---
title: "\"Performance\" DUALITYBIO's annual loss expands to 2.595 billion RMB"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/280185524.md"
description: "DUALITYBIO-B announced its 2025 annual performance, with revenue recorded at RMB 1.852 billion, a year-on-year decrease of 4.6%. Losses expanded from RMB 1.05 billion in the previous year to RMB 2.595 billion, with a loss per share of RMB 39.8. No final dividend will be distributed"
datetime: "2026-03-23T15:05:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/280185524.md)
  - [en](https://longbridge.com/en/news/280185524.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/280185524.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/280185524.md) | [English](https://longbridge.com/en/news/280185524.md)


# "Performance" DUALITYBIO's annual loss expands to 2.595 billion RMB

DUALITYBIO-B (09606.HK) announced its 2025 annual results, with revenue recorded at RMB 1.852 billion, a year-on-year decrease of 4.6%. The loss expanded from RMB 1.05 billion in the previous year to RMB 2.595 billion, with a loss per share of RMB 39.8. No final dividend will be distributed

### 相關股票

- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [Penghua CSI HK Connect Health Care Composite ETF (513700.CN)](https://longbridge.com/zh-HK/quote/513700.CN.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md)
- [DUALITYBIO-B (09606.HK)](https://longbridge.com/zh-HK/quote/09606.HK.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)

## 相關資訊與研究

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md)
- [TransThera Sciences Widens Annual Loss Amid Continued R&D Spend](https://longbridge.com/zh-HK/news/281187419.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)
- [Biocytogen, Sihuan Pharmaceutical form strategic partnership on weight management drug R&D](https://longbridge.com/zh-HK/news/281347646.md)
- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-HK/news/281068292.md)